Business Context and Reporting Period
This Form 8-K was filed by Miragen Therapeutics, Inc. (trading symbol: MGEN) on February 6, 2020. The registrant is a biopharmaceutical company focused on developing RNA-targeted therapeutics. The filing primarily discloses a proposed public offering of common stock and warrants and provides preliminary financial data for the year ended December 31, 2019.
Key Financial Metrics
- Cash Position: The company reported preliminary, unaudited cash, cash equivalents, and short-term investments of approximately $26.8 million as of December 31, 2019.
- Revenue and Profit: The filing text does not provide specific values for revenue, net income, or operating margins for the period.
- Debt and Liquidity: No specific debt figures are disclosed in this text. Liquidity is indicated by the preliminary cash balance of $26.8 million.
- Audit Status: The financial data is unaudited and subject to change pending the completion of audited financial statements by KPMG LLP.
Material Changes and Corporate Events
- Proposed Offering: On February 6, 2020, Miragen filed a preliminary prospectus supplement for a public offering of common stock and warrants to purchase common stock.
- Financial Update: The company provided an update on its cash position, noting that the $26.8 million figure is preliminary and may be adjusted materially upon final audit.
Guidance, Outlook, and Risks
Development Milestones
Management outlined the following anticipated milestones for 2020:
- Q2 2020: Report preclinical safety and efficacy data for MRG-229 (idiopathic pulmonary fibrosis).
- Q3 2020: Meet with the FDA regarding an expedited clinical development path for cobomarsen (adult T-cell leukemia/lymphoma).
- Q3 2020: Report topline data from the Phase 2 trial of cobomarsen (cutaneous T-cell lymphoma).
- 2H 2020: Report 12-month data from the Phase 2 trial of remlarsen (cutaneous fibrosis).
Risks and Contingencies
The filing includes standard forward-looking statement disclaimers. Key risks include uncertainties regarding the completion of the public offering on anticipated terms, market conditions, and the inherent uncertainties of clinical trial initiation and results. The company disclaims any obligation to update these statements except as required by law.
Investor Verification Checklist
- Verify the final audited cash balance for the year ended December 31, 2019, once the audit is complete, as the $26.8 million figure is preliminary.
- Confirm the final terms and completion status of the proposed public offering of common stock and warrants.
- Monitor the actual timing and results of the clinical milestones for MRG-229, cobomarsen, and remlarsen against the Q2/Q3/2H 2020 schedule.
- Review the full risk factors detailed in the company's Form 10-Q for the quarter ended September 30, 2019.